e-therapeutics plc

("e-therapeutics" or the "Company")

Filing of four new patent applications on novel target innovation and

new siRNA chemistries   

London, UK, 07 February 2023- e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces the filing of four new patent applications to protect innovation around novel gene targets, associated disease relevant biology as well as proprietary siRNA ('short interfering RNA') stabilisation chemistries.

The four new patent applications add to a rapidly growing patent portfolio reflecting the Company's continued intense rate of innovation associated with developing a computationally driven in-house pipeline of RNAi drug candidates across a range of therapeutic areas. The new patent applications build on an active period of IP generation reported in 2022 where a series of patent applications were filed to protect 13 inventions. 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: 

"This latest announcement of patent filings reflects our continued pace of innovation and progress towards an in-house pipeline of first-in-class RNAi candidates derived from our computational platform. We will continue to build on this progress, maintain the momentum of invention and actively protect our expanding intellectual property portfolio." 

Enquiries:

About e-therapeutics plc www.etherapeutics.co.uk

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines.  The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.  

ETX's proprietary Computational Biology Platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery that explicitly considers the true complexity of biology and makes more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data and information resource.  The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence. 

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by ETX's Computational Biology Platform.  The focus on hepatocytes offers the opportunity to work across a wide variety of diseases.  The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health.  ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action. 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates in several therapeutic areas including haematology, cardiovascular disease and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.